Cite this article
Volume | Year
European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.
The antibody-based CA125-targeted maintenance therapy for the epithelial ovarian cancer: a meta-analysis
1 Laboratory of Genetics, West China Institute of Women and Children's Health, West China Second Hospital, Sichuan University, Chengdu, China
2 Department of Obstetrics and Gynecology, West China Second Hospital, Sichuan University, Chengdu, China
3 Key Laboratory of Obstetric, Gynecologic and Pediatric Diseases and Birth Defects of Ministry of Education, Chengdu, China
Eur. J. Gynaecol. Oncol. 2016, 37(4), 455–460; https://doi.org/10.12892/ejgo2861.2016
Published: 10 August 2016
Objectives: To assess the effect and toxicity of CA125-targeted antibody used as maintenance therapy for advanced epithelial ovarian cancer (EOC). Materials and Methods: Two reviewers searched PubMed, Medline, Embase, VIP databases, and the references of selected articles for randomized controlled trials comparing maintenance CA125-targeted antibody treatment with placebo/observation. One-, two-, three-, and five-year overall survival (OS) and progression free survival (PFS) were collected. Incidence and severity of adverse events were extracted. Meta-analysis of combined risk ratio (RR) for OS , PFS, and toxicity were conducted. Results: Four trials including 1,259 women were identified. Meta-analysis showed the combined RR was 1.02 (95% CI, 0.85-1.22) for three-year OS and 0.98 (95% CI, 0.70-1.39) for the three-year PFS. This review found that abagovomab and oregovomab caused toxicity no more than placebo. Conclusions: CA125-targeted antibody used as maintenance therapy alone is not more effective than placebo but they were safe as maintenance therapy.
Epithelial ovarian cancer